We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch
Read MoreHide Full Article
Key Takeaways
TMO enrolled the first patient in its global PPD CorEvitas Alzheimer's Disease Registry.
TMO registry collects longitudinal, clinician-reported real-world data on therapy safety and effectiveness.
TMO's registry monitors MRI brain changes, plaque clearance and other safety events in real-world care.
Thermo Fisher Scientific Inc. (TMO - Free Report) recently announced the enrollment of the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry. The registry is designed as an international, multi-country initiative that will generate robust, harmonized, fit-for-purpose real-world data under a common global protocol. It will further support novel evaluations of drug safety and effectiveness that are critical for regulator, clinician, patient and caregiver communities.
TMO Stock Outlook Following the News
After the announcement, TMO shares dipped slightly 0.03% last Thursday.
On a positive note, the CorEvitas Alzheimer’s Disease Registry expands the growing portfolio of Thermo Fisher’s PPD CorEvitas Clinical Registries — proprietary disease registries that contain robust, structured clinician and patient-reported data from more than 500 investigator sites, with longitudinal data collected on over 100,000 patients. Hence, the news should favorably support TMO stock’s upward momentum.
Thermo Fisher has a market capitalization of $213.34 billion. The company’s earnings yield of 3.9% is well ahead of the industry’s -3.5% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.9%.
About TMO’s PPD CorEvitas Alzheimer’s Disease Registry
The registry has a longitudinal design, coupled with clinician-reported data from routine practice, which will generate a comprehensive understanding of Alzheimer’s therapy outcomes in real-world settings. The registry is expected to generate insights into long-term safety and treatment patterns, track the evolving use of approved therapies, identify unmet medical needs, clarify the disease’s impact on patients, and evaluate clinical outcomes associated with current treatment options.
Detailed monitoring and assessment of drug safety events are integral to the registry. This includes MRI-based evaluations of brain bleeding and swelling that may occur with certain treatments, as well as measures of plaque clearance — an important indicator of treatment effectiveness and its correlation with cognitive outcomes. This data will help generate a more complete understanding of safety and clinical outcomes in this patient population.
Industry Prospects Favor TMO
Alzheimer’s disease is a progressive neurodegenerative disorder that gradually damages brain cells, impairing memory, language, decision-making abilities and ultimately, the ability to perform daily tasks. Per a report published in PubMed Central, an estimated 7.2 million Americans aged 65 and older are living with Alzheimer.
Image Source: Zacks Investment Research
As a leading cause of death in the United States, the disease represents a significant public health challenge and underscores the need for rigorous evidence to guide therapeutic development and patient care (according to CDC report). Although there is currently no way to prevent or cure Alzheimer’s, treatments may help manage symptoms and potentially slow decline.
Another Development by TMO
Thermo Fisher recently announced the expansion of its Gibco Bacto CD portfolio. The Gibco Bacto CD Supreme FPM Plus and Gibco Bacto CD Supreme Feed (2X) are two next-generation chemically defined formulations to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli).
TMO Stock Price Performance
In the past year, TMO shares have risen 8.1% compared with the industry’s 1.2% growth.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Estimates for BrightSpring Health Services’ 2025 EPS have increased 5.7% in the past 30 days. Shares of the company have surged 94.8% in the past year compared with the industry’s 6.7% growth. BTSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.1%. In the last reported quarter, it delivered an earnings surprise of 11.1%.
Illumina shares have lost 5.7% over the past year. Estimates for the company’s 2025 EPS have jumped 0.9% to $4.71 in the past 30 days. ILMN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 6.7%. In the last reported quarter, it posted an earnings surprise of 15.5%.
Insulet shares have risen 10.7% over the past year. Estimates for the company’s 2025 EPS have increased 6.5% to $4.89 in the past 60 days. PODD’s earnings topped estimates in each of the trailing four quarters, delivering an average surprise of 17.8%. In the last reported quarter, it posted an earnings surprise of 9.7%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch
Key Takeaways
Thermo Fisher Scientific Inc. (TMO - Free Report) recently announced the enrollment of the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry. The registry is designed as an international, multi-country initiative that will generate robust, harmonized, fit-for-purpose real-world data under a common global protocol. It will further support novel evaluations of drug safety and effectiveness that are critical for regulator, clinician, patient and caregiver communities.
TMO Stock Outlook Following the News
After the announcement, TMO shares dipped slightly 0.03% last Thursday.
On a positive note, the CorEvitas Alzheimer’s Disease Registry expands the growing portfolio of Thermo Fisher’s PPD CorEvitas Clinical Registries — proprietary disease registries that contain robust, structured clinician and patient-reported data from more than 500 investigator sites, with longitudinal data collected on over 100,000 patients. Hence, the news should favorably support TMO stock’s upward momentum.
Thermo Fisher has a market capitalization of $213.34 billion. The company’s earnings yield of 3.9% is well ahead of the industry’s -3.5% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.9%.
About TMO’s PPD CorEvitas Alzheimer’s Disease Registry
The registry has a longitudinal design, coupled with clinician-reported data from routine practice, which will generate a comprehensive understanding of Alzheimer’s therapy outcomes in real-world settings. The registry is expected to generate insights into long-term safety and treatment patterns, track the evolving use of approved therapies, identify unmet medical needs, clarify the disease’s impact on patients, and evaluate clinical outcomes associated with current treatment options.
Detailed monitoring and assessment of drug safety events are integral to the registry. This includes MRI-based evaluations of brain bleeding and swelling that may occur with certain treatments, as well as measures of plaque clearance — an important indicator of treatment effectiveness and its correlation with cognitive outcomes. This data will help generate a more complete understanding of safety and clinical outcomes in this patient population.
Industry Prospects Favor TMO
Alzheimer’s disease is a progressive neurodegenerative disorder that gradually damages brain cells, impairing memory, language, decision-making abilities and ultimately, the ability to perform daily tasks. Per a report published in PubMed Central, an estimated 7.2 million Americans aged 65 and older are living with Alzheimer.
Image Source: Zacks Investment Research
As a leading cause of death in the United States, the disease represents a significant public health challenge and underscores the need for rigorous evidence to guide therapeutic development and patient care (according to CDC report). Although there is currently no way to prevent or cure Alzheimer’s, treatments may help manage symptoms and potentially slow decline.
Another Development by TMO
Thermo Fisher recently announced the expansion of its Gibco Bacto CD portfolio. The Gibco Bacto CD Supreme FPM Plus and Gibco Bacto CD Supreme Feed (2X) are two next-generation chemically defined formulations to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli).
TMO Stock Price Performance
In the past year, TMO shares have risen 8.1% compared with the industry’s 1.2% growth.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Illumina (ILMN - Free Report) and Insulet (PODD - Free Report) . While BrightSpring and Illumina sport a Zacks Rank #1 (Strong Buy) each, Insulet carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for BrightSpring Health Services’ 2025 EPS have increased 5.7% in the past 30 days. Shares of the company have surged 94.8% in the past year compared with the industry’s 6.7% growth. BTSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.1%. In the last reported quarter, it delivered an earnings surprise of 11.1%.
Illumina shares have lost 5.7% over the past year. Estimates for the company’s 2025 EPS have jumped 0.9% to $4.71 in the past 30 days. ILMN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 6.7%. In the last reported quarter, it posted an earnings surprise of 15.5%.
Insulet shares have risen 10.7% over the past year. Estimates for the company’s 2025 EPS have increased 6.5% to $4.89 in the past 60 days. PODD’s earnings topped estimates in each of the trailing four quarters, delivering an average surprise of 17.8%. In the last reported quarter, it posted an earnings surprise of 9.7%.